Iovance Biotherapeutics
IOVA
301 hedge funds and large institutions have $1.79B invested in Iovance Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 101 increasing their positions, 86 reducing their positions, and 36 closing their positions.
58% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 36
17% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 86
5% more funds holding
Funds holding: 286 → 301 (+15)
1.75% more ownership
Funds ownership: 77.51% → 79.26% (+1.7%)
19% less capital invested
Capital invested by funds: $2.21B → $1.79B (-$424M)
21% less call options, than puts
Call options by funds: $28.9M | Put options by funds: $36.4M
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$22.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$19.3M |
| 3 |
BlackRock
New York
|
+$18.5M |
| 4 |
Morgan Stanley
New York
|
+$16.8M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$41.8M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$18.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$15.8M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.83M |
IOVA Hedge Fund Activity: Q4 2024 in Review
301 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2024, worth a combined $1.79B — down 19% from $2.21B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new IOVA positions and 36 closed out — a net gain of 21 holders — while 101 added to existing stakes and 86 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $22.4M. The largest seller was Perceptive Advisors, cutting an estimated $41.8M.
- 301 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2024, up from 286 in Q3 2024.
- Funds reported $1.79B of Iovance Biotherapeutics stock for Q4 2024, down 19% quarter-over-quarter.
- 57 funds opened new Iovance Biotherapeutics positions in Q4 2024 and 36 closed out, a net change of +21 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2024 was Man Group, an estimated $22.4M added.
- The largest Iovance Biotherapeutics seller in Q4 2024 was Perceptive Advisors, an estimated $41.8M sold.
Based on aggregated 13F filings for Q4 2024.